An increase in soluble C5a levels has been described in serum and that of C5aR1 expression in blood and pulmonary myeloid cells in severe cases, suggesting a role for the C5a–C5aR1 axis in the pathophysiology of ARDS in COVID-19 patients [10]. This evidence concerns the gene C5AR1 and COVID-19.